Pulse Biosciences, Inc (NASDAQ:PLSE) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Pulse Biosciences has a “Moderate Buy” consensus from five analysts, with four buy ratings and one sell rating. The average 12-month price target is $45.25, including a recent Needham target of $58.
• PLSE shares opened at $44.54, near their 52-week high of $46.97, and have risen well above their 50-day and 200-day moving averages. Institutional investors own approximately 76.95% of the company.
• The company’s latest quarterly results fell short of expectations, with an adjusted loss of $0.36 per share versus the $0.29 expected and revenue of $0.43 million versus $0.53 million. Analysts project a full-year loss of $1.29 per share.

Shares of Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) have received an average recommendation of "Moderate Buy" from the five analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $45.25.

PLSE has been the subject of several research reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Needham & Company LLC started coverage on shares of Pulse Biosciences in a report on Monday. They issued a "buy" rating and a $58.00 price objective for the company. Canaccord Genuity Group raised their price target on shares of Pulse Biosciences from $32.00 to $43.00 and gave the company a "buy" rating in a research report on Monday, August 10th. Mizuho set a $45.00 target price on Pulse Biosciences in a report on Monday, August 10th. Finally, Oppenheimer restated an "outperform" rating on shares of Pulse Biosciences in a report on Tuesday, July 28th.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in PLSE. BNP Paribas Financial Markets boosted its position in shares of Pulse Biosciences by 63.6% in the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company's stock worth $26,000 after buying an additional 680 shares during the period. Osterweis Capital Management Inc. bought a new position in shares of Pulse Biosciences in the second quarter valued at approximately $28,000. Tower Research Capital LLC TRC boosted its holdings in Pulse Biosciences by 275.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company's stock worth $44,000 after buying an additional 2,156 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Pulse Biosciences by 13.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company's stock worth $70,000 after buying an additional 619 shares during the period. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Pulse Biosciences in the 2nd quarter valued at about $158,000. Hedge funds and other institutional investors own 76.95% of the company's stock.

Pulse Biosciences Stock Performance

PLSE stock opened at $44.54 on Monday. The firm has a 50-day simple moving average of $30.86 and a two-hundred day simple moving average of $24.74. Pulse Biosciences has a one year low of $12.56 and a one year high of $46.97. The firm has a market cap of $3.08 billion, a price-to-earnings ratio of -37.75 and a beta of 1.61.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.07). Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%.The company had revenue of $0.43 million during the quarter, compared to analysts' expectations of $0.53 million. As a group, equities analysts predict that Pulse Biosciences will post -1.29 earnings per share for the current fiscal year.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source